Comparison
While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38.
While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38.
CJC-1295 is 29 amino acids long, whereas FOXO4-DRI is shorter as it has a length of amino acids. CJC-1295 is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Glutamine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Alanine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Leucine, Serine, Arginine. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset.
CJC-1295
GHRH
FOXO4-DRI
FOXO4